Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of MEDPACE LABORATORIES is < 0.1% (very low). The 2024 annual accounts show equity of €15.66M and a net result of €1.46M. Equity is growing by ~23.2% per year across the filed fiscal years. Its solvency ranks better than 58% of 255 sector peers (fiscal year 2024). The company has been active since 2006 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 5 annual accounts.
Signals
1 signal · with evidenceConsistently profitable
Positive net result in the two most recent financial years (2023 and 2024).
View the result trend Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.
Filing behaviour
From the deposit records, complete market-wideDeadline passed, not yet counted as missing
The deadline for the year that closed on 31-12-2025 passed on 31-07-2026, 13 days ago. Our copy of the deposit register trails the National Bank (measured: median 14 days, p99 45 days), so we only call this filing missing from 45 days past the deadline.
Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 09-09-2025, 40 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
How we compute the deadline
The year end is derived from 10 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2024, that is 31-07-2025.
Deadline per financial year
| Year closed | Due by | Filed | Variance | Reference |
|---|---|---|---|---|
| 31-12-2025 | 31-07-2026 | nothing on record | not filed | - |
| 31-12-2024 | 31-07-2025 | 09-09-2025 | 40 d late | 2025-00486814 |
| 31-12-2023 | 31-07-2024 | 30-07-2024 | 1 d early | 2024-00310816 |
| 31-12-2022 | 31-07-2023 | 19-07-2023 | 12 d early | 2023-00254190 |
| 31-12-2021 | 31-07-2022 | 30-08-2022 | 30 d late | 2022-20345186 |
| 31-12-2020 | 31-07-2021 | 28-07-2021 | 3 d early | 2021-42500467 |
| 31-12-2019 | 31-07-2020 | 02-07-2020 | 29 d early | 2020-25100433 |
| 31-12-2018 | 31-07-2019 | 31-07-2019 | on the day | 2019-42600325 |
| 31-12-2017 | 31-07-2018 | 31-08-2018 | 31 d late | 2018-55200203 |
| 31-12-2016 | 31-07-2017 | 31-08-2017 | 31 d late | 2017-59600253 |
| 31-12-2015 | 31-07-2016 | 28-07-2016 | 3 d early | 2016-36900122 |
Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.
Trust signals
2 signalsLong-established
Founded in 2006, 20 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone< 0.1%
Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector
−Long track record
−Annual accounts: healthy financial profile
−
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Financials
Turnover€57.12M-0.8%
EBIT margin3.4%0pp
Net result€1.46M-9.9%
Working capital€-193k-47.9%
Annual accounts & ratios
Source: NBB · 2024Annual accounts filed on 09-09-2025 with the NBB · fiscal year 2024 · volledig
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~23.2%/year over 5 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2024 · NACE 86, Human health · compared within the same schema type (full schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 58.9% | 49.4% | |
| Net result | €1.46M | €50k | |
| Equity | €15.66M | €126k | |
| Staff costs | €11.67M | €156k | |
| Employees (FTE) | 160.4 | 4.1 |
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
P58
Improving position over 2020-2024
· n=78-255
P95
Stable position over 2020-2024
· n=78-254
P95
Stable position over 2020-2024
· n=78-255
P95
Stable position over 2021-2024
· n=72-114
Describes the position versus peers, not a forecast.
€57.12M
-0.8%
18-24
€3.30M
+2.1%
18-24
€1.46M
-9.9%
18-24
€2.82M
-2.5%
18-24
€26.60M
-8.5%
18-24
€15.66M
+10.3%
18-24
€-193k
-47.9%
18-24
160
-0.3%
18-24
€11.67M
+2.0%
18-24
€545k
+58.8%
18-24
€10.84M
-27.1%
18-24
€10.84M
-27.1%
18-24
0.98
-0.9%
18-24
0.61
-6.9%
18-24
58.9%
+20.6%
18-24
0.69
-33.9%
18-24
9.4%
-18.4%
18-24
5.5%
-1.5%
18-24
2.6%
-9.2%
18-24
5.8%
+2.9%
18-24
173.10
-58.0%
18-24
Figures by fiscal year
| Fiscal year | 2024 |
|---|---|
| Deposit | volledig |
| Revenue | €57.12M |
| EBITDA | €3.30M |
| Net profit | €1.46M |
| Cash flow | €2.82M |
| Staff costs | €11.67M |
| Income taxes | €545k |
| Dividends | - |
| Total assets | €26.60M |
| Equity | €15.66M |
| Debt | €10.84M |
| of which ≤ 1y | €10.84M |
| of which > 1y | - |
| Working capital | €-193k |
| Employees (FTE) | 160.4 |
Ratios (computed)
| 2024 | |
|---|---|
| Current ratio | 0.98 |
| Quick ratio | 0.61 |
| Working capital ratio | -0.7% |
| Solvency | 58.9% |
| Debt / equity | 0.69 |
| Long-term debt ratio | - |
| Interest coverage | 173.10 |
| Gross margin | 73.0% |
| Net margin | 2.6% |
| ROA | 5.5% |
| ROE | 9.4% |
| EBITDA margin | 5.8% |
| Days sales outstanding | 13d |
| Days payable outstanding | 92d |
| Inventory turnover | 3.79 |
| Days inventory (DSI) | 96d |
Balance-sheet composition 2024
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €26.60M |
| Fixed assets | 21/28 | €15.94M |
| Tangible fixed assets | 22/27 | €15.88M |
| Financial fixed assets | 28 | €62k |
| Current assets | 29/58 | €10.65M |
| Stocks & contracts in progress | 3 | €4.07M |
| Amounts receivable within one year | 40/41 | €4.04M |
| Cash & bank | 54/58 | €1.48M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €26.60M |
| Equity | 10/15 | €15.66M |
| Contributions / capital | 10/11 | €8.20M |
| Reserves | 13 | €400k |
| Accumulated profits (losses) | 14 | €7.06M |
| Provisions & deferred taxes | 16 | €89k |
| Amounts payable | 17/49 | €10.84M |
| Amounts payable within one year | 42/48 | €10.84M |
| Trade debts payable within one year | 44 | €3.89M |
| Income statement | ||
| Turnover | 70 | €57.12M |
| Operating result | 9901 | €1.95M |
| Financial income | 75 | €82k |
| Financial charges | 65 | €19k |
| Result before taxes | 9903 | €2.01M |
| Income taxes | 67/77 | €545k |
| Net result for the period | 9904 | €1.46M |
| Result to be appropriated | 9905 | €1.46M |
You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan.
See plans →
Ratios computed by Checked.
Health barometer
FY 2024 · computed63
/ 100
Healthy
Computed from 6 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.
Directors
Directors & mandates
3 directorsCurrent directors & mandates
-
Current01-02-2021 → present
-
Current01-02-2021 → present
Former directors (1)
-
Former- → 01-02-2021
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Statutory auditor
1 auditor| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| Deloitte bedrijfsrevisoren CVBA Statutory auditor · represented by Dominique Roux |
- | 11-12-2013 → 23-02-2016 |
Appointed statutory auditor from the Belgian State Gazette. The IRE/IBR number refers to the register of the Institute of Registered Auditors.
Insolvency mandates
No insolvency mandates (liquidators, administrators) on record for this company.
Legal Structure
| NACE primary | Activiteiten van medische beeldvorming en medische laboratoria(86910) |
| Legal form | Private limited company(610) |
| Incorporation | 20-02-2006 |
| Status | Active |
| Postal code | 3001 |
Structure & network
Connections & network
15 connected companiesNetwork connections
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.
Locations & real estate
Registered office
from the Crossroads BankCannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Technologielaan 193001 LeuvenEstablishment units
1 locationMedpace Reference Laboratories (MRL)
since 20062.151.874.229
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area7,100 m²
Buildings1
Building footprint480 m²
Volume (LiDAR)75 m³
Tallest building5.2 m
Real-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24514C0079/00Y000 | Flanders | 7,100 m² | 1 · 480 m² | 5.2 m |
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Publications
Lifecycle & Insolvency Signals
No insolvency signals in the Belgian State Gazette
Belgisch Staatsblad · acts
18 acts All acts · 18
updated 7 months ago
2026
09-01-2026 Change in the board of directors
Summary:
v3.2
2025
16-01-2025 Nico Houthaeve reappointed as statutory auditor
2023
28-12-2023 Articles of association amended
Summary:
v3.2
27-02-2023 Publication in the Belgian Official Gazette, Miscellaneous
Summary:
Substantive delegationNotary:
Marc SLEDSENS · AntwerpenFirm:
Deckers notarissen
2022
20-05-2022 Publication in the Belgian Official Gazette, Miscellaneous
Summary:
Substantive delegationNotary:
Marc SLEDSENS · AntwerpenFirm:
Deckers notarissen
2021
27-12-2021 Publication in the Belgian Official Gazette, Miscellaneous
Summary:
otherNotary:
Marc SLEDSENS · AntwerpenFirm:
Deckers notarissen
02-04-2021 Publication in the Belgian Official Gazette, Miscellaneous
Summary:
Substantive delegationNotary:
Marc SLEDSENS · AntwerpenFirm:
Deckers notarissen
03-03-2021 2 directors appointed, 1 resigning
- EWALD Stephen Paul, Bestuurder
- GEIGER Jesse Jacob, Bestuurder
- TROENDLE August James, Bestuurder
Summary:
v3.2
2020
18-02-2020 Articles of association amended
Summary:
v3.2
2018
17-10-2018 Dominique Roux reappointed as statutory auditor
2017
14-12-2017 Change in the board of directors
Summary:
v3.2
31-10-2017 Change in the board of directors
Summary:
v3.2
23-05-2017 Change in the board of directors
Summary:
v3.2
04-05-2017 Change in the board of directors
Summary:
v3.2
23-03-2017 Change in the board of directors
Summary:
v3.2
09-01-2017 Change in the board of directors
Summary:
v3.2
2016
23-02-2016 Dominique Roux reappointed as statutory auditor
2013
11-12-2013 Dominique Roux reappointed as statutory auditor
Analysis
Snowflake analysis
financial profile on 5 axes72
/ 100
Strong profile, led by stability.
All 5 axes are computed from data Checked has read.
Health
63
Profitability
38
Solvency
76
Growth
85
Stability
100
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soonAI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works
Credit advice
verdict per customer and amountSimilar
Similar companies
Comparable size, same sectorBE 0783.590.249 · Hoegaarden
BE 0405.775.051 · Leuven
BE 0440.543.118 · Charleroi
BE 0419.061.477 · Brussel
BE 0877.865.242 · Leuven
We hold annual accounts for 97 of the 699 companies in this sector. 10 of them are within a factor 10 of this company's equity.
Company registry
Company registry (CBE)
Crossroads BankActivities
Medische laboratoria85141Activiteiten van medische laboratoria86901Activiteiten van medische beeldvorming en medische laboratoria86910
Primary activity highlighted.
Names & trade names
| Legal nameNL | MEDPACE LABORATORIES |
Registered office
Technologielaan 19
3001 Leuven, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.